[Experimental bases and primary trials of photochemotherapy of psoriasis by a non-cancerigenic monofunctional furocoumarin, 3-carbethoxypsoralen].
The carcinogenic risk of the photochemotherapy (PUVA) with bifunctional furocoumarins such as 8-methoxypsoralen (8-MOP) forming cross-links in cellular DNA has initiated a search for active but less dangerous psoralens. The 3-carbethoxypsoralen (3-CPs), studied in the yeast Saccharomyces cerevisiae, has been very photoactive on DNA forming only monoadditions to DNA. In Mice it was demonstrated that after local or intra-peritoneal administration, 3-CPs is non toxic, non erythematogenic and non carcinogenic in contrast to 8-MOP. A limited study on ten psoriatic patients has shown that after local application 3-CPs exhibits about the same therapeutic activity as 8-MOP.
D000818:Animals; D004247:DNA / Q000528:radiation effects; D004272:DNA, Mitochondrial / Q000528:radiation effects; D011564:Furocoumarins / Q000494:pharmacology / Q000627:therapeutic use*; D006801:Humans; D008730:Methoxsalen / Q000494:pharmacology; D051379:Mice; D010778:Photochemotherapy; D011565:Psoriasis / Q000188:drug therapy*; D012441:Saccharomyces cerevisiae / Q000187:drug effects / Q000528:radiation effects
D004272:DNA, Mitochondrial; D011564:Furocoumarins; D004247:DNA; D008730:Methoxsalen
Bases expérimentales et premiers essais d'une photochimiothérapie du psoriasis par une furocoumarine monofonctionnelle non cancérigène, le 3-carbethoxypsoralène.